MyFinsight
Home
Compare
About
Recent SEC Filings
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
10/2
NIKE, Inc.
(NKE)
10/2
DARDEN RESTAURANTS INC
(DRI)
9/30
CONAGRA BRANDS INC.
(CAG)
9/29
Carnival Corp Ltd.
(CCL)
9/29
URANIUM ENERGY CORP
(UEC)
9/29
COPART INC
(CPRT)
9/24
BLACKBERRY Ltd
(BB)
9/24
PAYCHEX INC
(PAYX)
9/23
GENERAL MILLS INC
(GIS)
9/22
ADOBE INC.
(ADBE)
9/18
KROGER CO
(KR)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
|
Compare
Income Overview
Revenue
$63,693K
Net Income
$48,508K
Net Profit Margin
76.16%
EPS
$2.22
Unit: Thousand (K) dollars
Revenue Breakdown
Filspari
Material Sales Captisol
Kyprolis
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenues and income
63,693
51,722
-78,296*
115,461
Cost of captisol
3,214
3,273
3,146*
3,801
Amortization of intangibles
8,097
8,097
8,417*
8,097
Research and development
14,668
2,148
18,125*
21,019
General and administrative
29,123
20,836
7,111*
28,446
Financial royalty assets impairment
-
-
6,197*
0
Fair value adjustments to partner program derivatives
0
0
-2,499*
833
Total operating costs and expenses
55,102
34,354
45,495*
60,530
Gain on sale of pelican
-
-
0*
-
Operating income (gain)
8,591
17,368
-123,791*
54,931
Loss (gain) from short-term investments
11,754
3,869
-4,961*
7,798
Loss (gain) from change in fair value of equity-method investments and other investments
35,727
-49,229
-136,991*
75,887
Interest income
7,298
6,655
2,037*
3,874
Interest expense
1,748
1,747
1,985*
910
Other non-operating expense, net
2,682
-1,175
1,240*
-443
Total non-operating income (expenses), net
55,713
-41,627
-140,660*
86,206
Income (gain) before income taxes
64,304
-24,259
-264,451*
141,137
Income tax (expense) benefit
15,796
-10,914
-37,085*
23,864
Net income (loss) from continuing operations
-
-
-227,366
-
Net income (gain)
48,508
-13,345
-227,366
117,273
Basic EPS
2.42
-0.67
-11.905
5.99
Diluted EPS
2.22
-0.67
-11.392
5.68
Basic Average Shares
20,063,000
19,883,000
19,098,000
19,578,000
Diluted Average Shares
21,837,000
19,883,000
19,959,000
20,629,000
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
LGNZZ Income Statement Sankey Diagram
Sankey diagram visualizing LGNZZ income statement for the period
Filspari
$13,567K
Kyprolis
$7,044K
Royalty Intangible
Other
$4,269K
Intangible Ohtuvayre
$4,144K
Rylaze
$3,201K
Capvaxive
$2,316K
Teriparatide Injection
$1,470K
Vaxneuvance
$1,351K
QARZIBA
$6,150K
Financial Ohtuvayre
Inventors
$3,294K
Financial Royalty Other
$1,226K
Intangible Royalty Assets
$37,362K
Financial Royalty Assets
$10,670K
Contract And Revenue
Income Other
$5,000K
Contract Revenue
$2,683K
Royalty
$48,032K
Material Sales Captisol
$7,978K
Contract Revenue And
Other Income
$7,683K
Loss (gain) from
change in fair value of...
$35,727K
Loss (gain) from
short-term investments
$11,754K
Interest income
$7,298K
Other non-operating
expense, net
$2,682K
Total revenues and
income
$63,693K
Total non-operating
income (expenses), net
$55,713K
Operating income (gain)
$8,591K
Interest expense
$1,748K
Total operating costs
and expenses
$55,102K
Income (gain) before
income taxes
$64,304K
General and
administrative
$29,123K
Research and development
$14,668K
Amortization of intangibles
$8,097K
Cost of captisol
$3,214K
Net income (gain)
$48,508K
Income tax (expense)
benefit
$15,796K
Buy us a coffee
LIGAND PHARMACEUTICALS INC (LGNZZ)
LIGAND PHARMACEUTICALS INC (LGNZZ)